Hector Salazar

Hector Salazar

Auto-generated profile, based on publicly available information

Hector Salazar

Department of Health and Community Systems, University of Pittsburgh School of Nursing , Pittsburgh, Pennsylvania

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2024 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
CGCarey E Gleason
Carey E Gleason
MARITZA Maritza DOWLINGMARITZA Maritza DOWLING
MARITZA Maritza DOWLING
FKFirat Kara
Firat Kara
TJTaryn T James
Taryn T James
HSHector Salazar
Hector Salazar
KKKejal Kantarci
Kejal Kantarci
Background: Findings from Kronos Early Estrogen Prevention Study (KEEPS)-Cog trial suggested no cognitive benefit or harm after 48 months of menopausal hormone therapy (mHT) initiated within 3 years of final menstrual period. To clarify the long-term effects of mHT initiated in early postmenopause, the observational KEEPS Continuation Study reevaluated cognition, mood, and neuroimaging effects in participants enrolled in the KEEPS-Cog and its parent study the KEEPS approximately 10 years after trial completion. We hypothesized that women randomized to transdermal estradiol (tE2) during early postmenopause would show cognitive benefits, while oral conjugated equine estrogens (oCEE) would show no effect, compared to placebo over the 10 years following randomization in the KEEPS trial. Methods and findings: The KEEPS-Cog (2005–2008) was an ancillary study to the KEEPS (NCT00154180), in which participants were randomized into 3 groups: oCEE (Premarin, 0.45 mg/d), tE2 (Climara, 50 μg/d) both with micronized progesterone (Prometrium, 200 mg/d for 12 d/mo) or placebo pills and patch for 48 months. KEEPS Continuation (2017–2022), an observational, longitudinal cohort study of KEEPS clinical trial, involved recontacting KEEPS participants approximately 10 years after the completion of the 4-year clinical trial to attend in-person research visits. Seven of the original 9 sites participated in the KEEPS Continuation, resulting in 622 women of original 727 being invited to return for a visit, with 299 enrolling across the 7 sites. KEEPS Continuation participants repeated the original KEEPS-Cog test battery which was analyzed using 4 cognitive factor scores and a global cognitive score. Cognitive data from both KEEPS and KEEPS Continuation were available for 275 participants. Latent growth models (LGMs) assessed whether baseline cognition and cognitive changes during KEEPS predicted cognitive performance at follow-up, and whether mHT randomization modified these relationships, adjusting for covariates. Similar health characteristics were observed at KEEPS randomization for KEEPS Continuation participants and nonparticipants (i.e., women not returning for the KEEPS Continuation). The LGM revealed significant associations between intercepts and slopes for cognitive performance across almost all domains, indicating that cognitive factor scores changed over time. Tests assessing the effects of mHT allocation on cognitive slopes during the KEEPS and across all years of follow-up including the KEEPS Continuation visit were all statistically nonsignificant. The KEEPS Continuation study found no long-term cognitive effects of mHT, with baseline cognition and changes during KEEPS being the strongest predictors of later performance. Cross-sectional comparisons confirmed that participants assigned to mHT in KEEPS (oCEE and tE2 groups) performed similarly on cognitive measures to those randomized to placebo, approximately 10 years after completion of the randomized treatments. These findings suggest that mHT poses no long-term cognitive harm; conversely, it provides no cognitive benefit or protective effects against cognitive decline. Conclusions: In these KEEPS Continuation analyses, there were no long-term cognitive effects of short-term exposure to mHT started in early menopause versus placebo. These data provide reassurance about the long-term neurocognitive safety of mHT for symptom management in healthy, recently postmenopausal women, while also suggesting that mHT does not improve or preserve cognitive function in this population.

13 February 2025 in Innovation in Aging
Verified
Journal Article
Open access
HSHector Salazar
Hector Salazar
CGCarey E Gleason
Carey E Gleason
JLJennifer H Lingler
Jennifer H Lingler
Black Americans are two to three times more likely to develop ADRD than their white counterparts, yet Black Americans make up only 2.4% of ADRD clinical trial participants. Here we provide an overview of the current state of initiatives to maximize racial and ethnic inclusivity in clinical research, particularly among ethnoracialized groups, and introduce the Indigenous-rooted concept of cultural safety through an integrative review and outline of its applicability to the research context. Cultural safety ensures that cultural identities, values, and experiences of minoritized persons are respected, understood, and integrated in their health care journey, empowering them to define and evaluate their own experiences. Implementing cultural safety challenges individuals to confront and critically examine their own perspectives on the dominant culture’s traditions and values, as well as their implicit racism, biases, privileges, and inherent power structures. We extend prior conceptual work on cultural safety by proposing two subdimensions: environmental and internal. These must be synergistically integrated to heal fractured relationships between communities of color and researchers. By championing cultural safety, we can create a workforce of self-aware researchers who embody cultural safety’s true essence as defined by the communities they serve. Community-engaged research serves as an ideal platform for cultural safety to be meaningfully implemented and sustained. This approach can uplift previously silenced voices in research, build long-term relationships, and generate empirical data that substantiates its positive effects. Importantly, applying environmental and internal cultural safety can empower participants in ADRD research where it is critically needed.

15 March 2025 in Innovation in Aging
Verified
Journal Article
Open access
JKJeong Eun Kim
Jeong Eun Kim
MKMelissa Knox
Melissa Knox
JGJoshua D Grill
Joshua D Grill
MWMegan Witbracht
Megan Witbracht
YZYuchen Zhang
Yuchen Zhang
JLJennifer H Lingler
Jennifer H Lingler
Background and Objectives: Remote data collection emerged as a valuable method for engaging vulnerable populations, such as individuals participating in Alzheimer’s disease and related dementias (ADRD) research. Despite challenges like technology readiness and privacy concerns, remote methods have the potential to enhance participation among diverse groups by offering flexibility while addressing accessibility barriers such as geographic distance. This study shares experiences with virtual data collection and the strategies employed to enhance ADRD research involving individuals with and at risk of cognitive impairment. Research Design and Methods: Experiences are drawn from RIDE (Recruitment Innovations for Diversity Enhancement), an online survey study to assess interest in ADRD research participation among presumably unimpaired adults identifying as Black or African American; and PARADE (Patient and Family Member Reactions to Biomarker-Informed ADRD Diagnoses), an observational, longitudinal cohort study of individuals receiving a biomarker-informed diagnosis for cognitive impairment and their care partners. We detail approaches employed across recruitment, data collection, to retention stages. Results: Virtual data collection was highly feasible in both studies, successfully engaging participants in ADRD research, including those from underrepresented racial and ethnic groups. In RIDE, although project staff occasionally needed to troubleshoot technical challenges (e.g., broken survey links, video issues), the study successfully recruited 500 adults identifying as Black/African American. PARADE showed that synchronous interviews minimized missing data, with care partners providing essential technical and logistical support. Despite occasional difficulties with video conferencing and participant payments, most participants remained fully engaged, highlighting the effectiveness of virtual methods and the need for continuous support to ensure successful participation. Discussion and Implications: Virtual data collection offers opportunities to promote inclusion in ADRD research, as demonstrated by the successful enrollment of diverse participant samples in both studies. Successful implementation requires careful planning to address challenges such as digital literacy, educational disparities, and technical support.

30 June 2024 in medRxiv
Verified
Preprint
Open access
PDF file
CGCarey E. Gleason
Carey E. Gleason
MARITZA Maritza DOWLINGMARITZA Maritza DOWLING
MARITZA Maritza DOWLING
FKFirat Kara
Firat Kara
TJTaryn T. James
Taryn T. James
HSHector Salazar
Hector Salazar
KKKejal Kantarci
Kejal Kantarci
Background: Findings from Kronos Early Estrogen Prevention Study (KEEPS)-Cog trial suggested no cognitive benefit or harm after 48 months of menopausal hormone therapy (mHT) initiated within three years of menopause onset. Long-term effects of mHT exposure during early postmenopause remain understudied. To clarify the long-term effects of mHT initiated in early postmenopause, the observational KEEPS-Continuation Study reevaluated cognition, mood, and neuroimaging effects in participants enrolled in the KEEPS-Cog and its parent study the KEEPS approximately 10 years after trial completion. We hypothesized that the participants randomized to one of two active estrogen formulations during early postmenopause would demonstrate differential longitudinal change in cognitive performance during the approximately ten years following randomization in the parent KEEPS trial when compared to women who received placebo. Specifically, transdermal estradiol (tE2) would demonstrate benefit over placebo, and oral conjugated equine estrogens (oCEE) demonstrate no effect compared to placebo. Methods and Findings: The KEEPS-Cog was an ancillary study to the KEEPS, in which women were randomized to placebo or one of two forms of mHT, oCEE (Premarin, 0.45 mg/d) or tE2 (Climara, 50 µg/d) for 48 months. Micronized progesterone (Prometrium, 200 mg/d) was used by those in mHT arms. Approximately 10 years (M(SD)=9.57(1.08) years; range: 8-14 years) after randomization, women returned to repeat the original KEEPS-Cog test battery. Cognitive tests were analyzed as 4 factor scores and a global cognitive score. Because KEEPS-Continuation visits occurred 8-14 years post-randomization, linear latent growth models with distal outcomes tested whether cognitive performance at baseline in KEEPS and the change-in-cognition across KEEPS visits predicted “distal” KEEPS cognition, and whether mHT randomization of KEEPS modified this relationship. Covariates included education, age at continuation visit, and APOE e 4 allele carrier status. All 727 postmenopausal participants in the KEEPS interventions were eligible for the KEEPS-Continuation. Among those participants, 622 (86%) had valid contact information and were invited to the study. Of these, 194 did not respond, 10 were deceased, and 119 declined to participate, resulting in 299 participants enrolled in the KEEPS-Continuation at seven sites. Of the 299 KEEPS-Continuation participants, 275 had cognitive data to estimate cognitive factors scores both at KEEPS and KEEPS-Continuation. Similar health characteristics were observed at KEEPS randomization for KEEPS-Continuation participants and nonparticipants (i.e. women not returning for the KEEPS-Continuation). Among the women enrolled in the KEEPS-Continuation, cognitive performance was not influenced by either mHT formulation employed in KEEPS. Models showed strong associations between baseline cognition and change-in-cognition during KEEPS and the same measures in KEEPS-Continuation, i.e., the strongest predictor of cognitive performance in KEEPS-Continuation was cognitive performance in KEEPS. KEEPS-Continuation cross-sectional comparisons confirmed that participants assigned to mHT in KEEPS (oCEE and tE2 groups) performed similarly on cognitive measures to those randomized to placebo, approximately 10 years after women completion of the randomized treatments. Conclusions: In these KEEPS-Continuation analyses, there were no long-term cognitive effects of short-term exposure to mHT started in early menopause vs. placebo. These data offer reassurance regarding long term neurocognitive safety of mHT used by healthy recently postmenopausal women for symptom management. Author summary: Why was this study done?: Little is known about the long-term cognitive effects of short-term use of menopausal hormone therapies (mHT) – i.e, the use of mHT during the menopausal transition or in early postmenopause for symptoms of menopause, leaving women and their providers with concerns about long-term consequences of short-term mHT use. We invited women who participated in a study examining the cognitive effects of short-term mHT to return for re-evaluation approximately a decade after they were randomized to 4 years of treatment with one of two forms of mHT or a placebo. Importantly, the original study only enrolled women who were recently postmenopausal and at low cardiovascular risk. The goals for the follow-up study were to examine the long-term cognitive effects of using mHT for a brief period shortly after menopause onset and to assess if these effects differed for the two forms of mHT. What did the researchers do and find?: > The observational Kronos Early Estrogen Prevention Study (KEEPS)-Continuation explored cognitive effects of short-term (4 year) randomized assignment to mHT vs. placebo, initiated within 3 years of menopause onset, after an average of 10 years following randomization in the original KEEPS trial. > We tested whether long term cognitive performance was influenced by prior exposure to HT formulation (e.g., transdermal 17β-estradiol or oral conjugated equine estrogens), controlling for covariates using linear latent growth models. > Among the women enrolled in the KEEPS-Continuation, cognitive performance was not influenced by earlier exposure to either HT formulation. > Linear growth models showed strong associations between baseline cognition (intercept) and its change (slope) during KEEPS and the same measures in the KEEPS-Continuation. > KEEPS-Continuation cross-sectional comparisons confirmed that both oral and transdermal mHT groups performed similarly to placebo on cognitive measures approximately 10 years after they were randomized to either HT or placebo. What do these findings mean?: > We detected no long-term cognitive benefit or harm of short-term mHT vs placebo. > Our findings suggest that there are no long-term cognitive effects of exposure to short-term mHT vs placebo in recently postmenopausal women who have low cardiovascular risk. > These data offer reassurance to recently postmenopausal women with good cardiovascular health who are considering mHT for the management of menopausal symptoms.